+

WO1999036548A1 - Tyrosine phosphatases proteiniques lymphoides humaines - Google Patents

Tyrosine phosphatases proteiniques lymphoides humaines Download PDF

Info

Publication number
WO1999036548A1
WO1999036548A1 PCT/CA1999/000038 CA9900038W WO9936548A1 WO 1999036548 A1 WO1999036548 A1 WO 1999036548A1 CA 9900038 W CA9900038 W CA 9900038W WO 9936548 A1 WO9936548 A1 WO 9936548A1
Authority
WO
WIPO (PCT)
Prior art keywords
lyp
protein
sequence
lypl
amino acid
Prior art date
Application number
PCT/CA1999/000038
Other languages
English (en)
Inventor
Chaim M. Roifman
Original Assignee
Hsc Research And Development Limited Partnership
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hsc Research And Development Limited Partnership filed Critical Hsc Research And Development Limited Partnership
Priority to AU20432/99A priority Critical patent/AU2043299A/en
Priority to CA002318697A priority patent/CA2318697A1/fr
Publication of WO1999036548A1 publication Critical patent/WO1999036548A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Definitions

  • This invention relates to a human phosphatase gene (Lyp) which encodes an intracellular tyrosine phosphatase (Lypl) and an isoform of Lypl, called Lyp2. More particularly, it relates to the cDNA sequence of human Lypl and Lyp2, the protein products and the expression, role and use of these phosphatases in humans.
  • Lyp human phosphatase gene
  • PTKs protein tyrosine kinases
  • PTPases protein tyrosine phosphatases
  • PTPases contain a catalytic domain of approximately 200-300 residues including a subset of highly conserved amino acids that play a role in substrate recognition and tyrosine dephosphorylation (3).
  • the PTPases family can be divided broadly into two major classes: membrane bound, receptor-like or receptor phosphatases and non-receptor or intracellular phosphatases (4, 5). Both types can be further subdivided into subfamilies based on their sequence similarities and non- catalytic domain structure motifs (6,7).
  • the receptor PTPases have one or two intracellular phosphatase domains and often have Ig-like domains and fibronectin-like extracellular regions (6) that play a role in cell-cell or cell-matrix interactions (8). In fact, some receptor PTPases appear to participate in homophilic and heterophilic binding interactions suggestive of a role in cell guidance and contact inhibition (7,8).
  • the non-receptor phosphatases display various intracellular localizations determined by amino acid sequences outside the catalytic domain (9, 35, 40). Some contain conserved non-catalytic domains such as the Src homology 2 (SH2) and SH3 domains allowing them to interact with a variety of tyrosine phosphorylated proteins and proteins containing proline rich sequences (19, 10, 11). Cytoplasmic PTPases have been found associated with a variety of PTKs including CSK and the Jak kinases, and a number of cytokine and antigen receptors (7, 11,31).
  • CD45 a transmembrane phosphatase expressed exclusively in hematopoietic cells (12), is required for antigenic activation of B and T lymphocytes (13, 14).
  • CD45-deficient mice indicates that CD45 also plays a pivotal role in thymic development and T cell apoptotic response to T cell receptor engagement (15, 16).
  • hematopoietic-specific intracellular phosphatase-SHPl SH2 containing PTPase
  • SHPl also participates in T cell signalling events through dephosphorylation ofthe T cell receptor (TCR), p56 lck and ZAP-70 (19). Mutations in the murine motheaten locus coding the SHPl protein result in severe combined immunodeficiency and systemic autoimmunity, as well as many other hematopoietic abnormalities (20). Furthermore, expression of HePTP, a cytoplasmic hematopoietic-specific PTPase, is induced in lymphocytes stimulated by phytohemagglutinin, concavalin A, lipopolysaccharide and anti-CD3 (21), suggestive of a role in lymphocyte activation pathways.
  • Lypl Lymphoid Protein Tyrosine Phosphatase gene
  • Lypl The phosphatase Lypl is involved in lymphocyte growth and development and is predominantly expressed in lymphoid cells. Lypl is an intracellular 105 kDa protein containing a single tyrosine phosphatase catalytic domain.
  • Lyp2 an isoform of Lypl has been identified and designated Lyp2.
  • Lyp2 This isoform is a product of C-terminal alternative RNA splicing resulting in a smaller 85 kDa protein.
  • the cDNA sequences encoding Lypl and Lyp2 have been cloned, sequenced and expressed to provide the respective proteins.
  • the proteins are most highly expressed in lymphoid tissues including spleen, lymph nodes, peripheral leukocytes, tonsil, bone marrow, thymocytes and in both immature and mature B and T lymphocytes. Lypl expression has been demonstrated to be induced by activation of resting peripheral T lymphocytes with PHA or anti-CD3.
  • Lypl has also been demonstrated to be constitutively associated with the proto-oncogene c-Cbl (a protein which is recognized to be important in the regulation ofthe Zap family kinases) in thymocytes and T cells. Overexpression of Lypl reduced Cbl tyrosine phosphorylation, suggesting it may be a substrate ofthe phosphatase. Lypl has also been demonstrated to down-regulate the activity ofthe T cell tyrosine kinase Zap-70, with little effect on Syk kinase. Lypl strongly down-regulates Lyn kinase activity, while Fyn function is unaffected. In B cells, Lyp is constitutively bound to the Syk kinase and inducibly binds a number of phosphorylated proteins after stimulation of the cell through the B cell receptor.
  • c-Cbl a protein which is recognized to be important in the regulation ofthe Zap family kinases
  • the invention provides an isolated polynucleotide comprising a nucleotide sequence encoding a Lyp protein.
  • the invention provides an isolated polynucleotide which encodes a Lyp protein having an amino acid sequence of greater than 70% overall identity to the amino acid sequence of Table 2.
  • the invention provides an isolated polynucleotide which encodes a Lyp protein having an amino acid sequence of greater than 70% overall identity to the amino acid sequence of Table 4.
  • the invention provides an isolated polynucleotide which encodes a Lyp protein having an amino acid sequence with at least 80%) overall identity, preferably at least 90%o overall identity to the amino acid sequence of Table 2.
  • the invention provides an isolated polynucleotide which encodes a Lyp protein having an amino acid sequence with at least 80% overall identity, preferably at least 90% overall identity to the amino acid sequence of Table 4.
  • the invention provides a nucleotide sequence comprising at least 10, preferably 15 and more preferably 20 consecutive nucleotides of Sequence ID NO: 1 or Sequence ID NO:3.
  • the invention provides a substantially purified Lyp protein.
  • the invention provides a substantially purified protein having an amino acid sequence of greater than 70%> overall identity to the amino acid sequence of Table 2.
  • the invention provides a substantially purified protein having an amino acid sequence of greater than 70% overall identity to the amino acid sequence of Table 4.
  • the invention provides a substantially purified protein having an amino acid sequence with at least 80%> overall identity, preferably at least 90%> overall identity, to the amino acid sequence of Table 2.
  • the invention provides a substantially purified protein having an amino acid sequence with at least 80% overall identity, preferably at least 90% overall identity, to the amino acid sequence of Table 4.
  • the invention provides a peptide comprising at least 5, preferably 10, more preferably 20 consecutive amino acids of Sequence ID NO:2 or Sequence ID NO:4.
  • the invention provides a peptide comprising at least one functional domain of a Lyp protein.
  • the invention provides a peptide comprising at least one antigenic determinant of a Lyp protein.
  • the invention provides an antibody which binds specifically to a Lyp protein.
  • the invention provides a method for screening a candidate compound for an ability to increase or decrease the phosphatase activity of a Lyp protein comprising
  • the invention provides a method for screening a candidate compound for ability to modulate expression of a Lyp gene comprising contacting a cell with a candidate compound, wherein the cell includes a regulatory region of a Lyp gene operably joined to a coding region; and detecting a change in expression ofthe coding region.
  • the invention provides a non-human animal wherein a genome of said animal, or of an ancestor thereof, has been modified by a modification selected from the group consisting of:
  • the invention provides a pharmaceutical composition comprising an active ingredient selected from the group consisting of:
  • the invention provides a method for treating a subject having a deficiency of Lyp activity comprising administering to the subject an effective amount of an agent selected from the group consisting of:
  • a pharmaceutical composition comprising an active ingredient selected from the group consisting of: an antisense sequence which hybridizes to a human Lypl nucleotide sequence or to a transcript ofthe sequence; a substantially pure antibody which binds selectively to human Lypl or Lyp2 protein and a pharmaceutically acceptable carrier; a mimetic of human Lypl or Lyp2 protein; a functional analog of human Lypl or Lyp2 protein; an inhibitor of human Lypl or Lyp2 protein activity; and an agent capable of altering the phosphorylation state of human Lypl or Lyp2 protein.
  • a method is provided of screening for an agent useful in treating a disorder characterized by an abnormality in a phosphorylation signaling pathway of lymphoid cells, wherein the pathway involves an interaction between a human Lypl or Lyp2 protein and a human Lypl or Lyp2 activator, comprising screening potential agents for ability to disrupt or promote the interaction as an indication of a useful agent.
  • a method is provided of preventing or treating a disorder in a mammal characterized by an abnormality in an intracellular phosphorylation signaling pathway of lymphoid cells, wherein the pathway involves an interaction between a human Lypl or Lyp2 protein and a human Lypl or Lyp2 substrate, comprising the step of disrupting or promoting said interaction in vivo.
  • Figure 1 shows a schematic diagram of Lypl and Lyp2 deduced from the cDNA clones. Boxes indicate the open reading frame, with thin lines representing the 5' and 3' untranslated regions. The six overlapping cDNA clones (bold black lines) obtained from a human thymus cDNA library are shown under the schematic structures ofthe cDNAs.
  • Figure 2 shows an alignment of Lypl and Z70PEP (Sequence ID NO:5) amino acid sequences.
  • the PTPase domain is indicated by brackets.
  • An arrow indicates the end ofthe amino acid sequence shared by Lypl and Lyp2 and the beginning ofthe unique C-terminal sequence of Lypl.
  • the NXXY motif is indicated by line above the sequence.
  • the four potential SH3 domain binding sites are also indicated (asterisks).
  • a consensus sequence is shown below the alignment.
  • the unique seven amino acids of Lyp2 are shown in the box below the alignment.
  • Figure 3 A (left panel) demonstrates the regional mapping ofthe Lyp gene by fluorescence in situ hybridization to normal human lymphocyte chromosomes counterstained with DAPI.
  • Biotinylated cDNA probe was detected with avidin- fluorescein isothiocyanate (FITC).
  • FITC avidin- fluorescein isothiocyanate
  • Figure 4 demonstrates that Lyp2 is a result of alternative splicing ofthe Lyp gene.
  • A schematic map ofthe PCR strategy used. Primer 1 corresponds to the last 20 nucleotides shared by both Lypl and Lyp2 sequences, primer 2 to Lyp2 untranslated area and primer 3 to the beginning ofthe novel Lypl sequence, immediately downstream of primer 1. (see also C).
  • B The results ofthe PCT amplification on genomic DNA. Lane 1 , DNA size markers, Lane 2, a product of 3.5kb was amplified with primers 1 and 3. Lane 3, is a product of lOObp was amplified with primers 1 and 2.
  • C Schematic map of Lypl splicing.
  • sequences before the vertical line represent the splice donor site, while the nucleotide sequences after it are the Lypl intronic sequence which code for the unique C-terminal seven amino acids, stop codon (asterisk) and untranslated sequence (lower case letters) of Lypl.
  • a white box represents the common cDNA sequence shared by Lypl and Lyp2, the black and the light gray boxes representing the unique sequences of each cDNA (Lypl and Lyp2 respectively).
  • Figure 5 shows the expression profile of Lypl and Lyp2 transcripts. The size of RNA markers are indicated in kb.
  • Figure 6 shows an immunoblot of transfected COS-7 cells.
  • T7 tagged Lypl A or Lyp2 (B) were transfected into COS-7 cells and immunoprecipitated with anti- Lyp or anti-T7 antibody and blotted with anti-T7.
  • Figure 7 shows in vivo translation of Lypl and Lyp2 proteins, COS-7 cells were transiently transfected with HA-tagged Lypl and Lyp2 cDNAs and protein expression analyzed by Western blotting with anti-HA tag antibodies.
  • Lane 1 pCDNA3.
  • Molecular mass markers are shown in kDa.
  • Figure 8 shows the relative quantification of Lypl and Lyp2 transcripts in thymocytes cDNA by competitive PCR. Different concentration of competitor DNA were added to fixed amount of sample cDNA. The results of PCR amplification products of (A) 26 cycles with specific primers to Lypl (B) 35 cycles with specific primers to Lyp2. The internal control concentrations are indicated below the pictures in Pico-Molar.
  • Figure 9 shows the localization of Lypl and Lyp2 in transiently transfected COS-7 cells by immunofluorescence.
  • COS-7 cells were transiently transfected with HA-tagged Lypl and Lyp2 cDNAs and immunofluorescence was performed using a monoclonal antibody against HA tag.
  • Magnification 1000X (A) Cells transfected with HA-Lyp2 cDNA. (B) Cells transfected with HA-Lypl cDNA.
  • Figure 10 shows Lyp protein expression in lymphoid and myeloid cell lines. Lyp was immunoprecipitated from cell lines (10 7 cells) and blotted with Lyp antibodies. A protein band of 105 kD corresponding to Lypl could be detected in Jurkat, Daudi, Ramos, Al and G2 cells, while U937and K562 do not appear to have detectable amounts of Lyp. (PB)- Pre-immune serum control.
  • FIG 11 shows the expression of Lyp proteins in resting and activated T cells.
  • PB Pre-immune serum controls
  • Figure 12 shows the measurement of Lypl phosphatase activity.
  • Anti-Lyp immunoprecipitates from untransfected and pcDNA3-Lypl transfected cells were prepared in pervanadate free lysis buffer and incubated with 3 P labelled substrate Raytide. At the indicated time points reactions were stopped by the addition of charcoal and the free 33 P released from the peptide and now present in the supernatant measured by liquid scintillation counting.
  • Figure 13 demonstrates the involvement of Lypl in TCR signaling.
  • Lyp immunoprecipitates from thymocytes (80 x 10 6 cells) stimulated with anti-CD3 were blotted with antiphsophotyrosine. A single phosphorylated band of 116 kD was detected co-immunoprecipitating with Lyp. Lyp protein loading was quantitated by anti-Lyp western blot after stripping.
  • B Immunoblotting with anti-Cbl identified the 116 kD phosphorylated protein as Cbl, while immunoblotting with anti-FAK or anti- pi 10 (subunit of PI-3 kinase) showed them not to be associated with Lyp.
  • C Lypl was transfected into COS-7 cells and Cbl immunoprecipitates prepared from these and untransfected cells. Western blotting was performed with Lyp antibodies. The position of Lyp is indicted by an arrow. Cbl immunoprecipitates were also prepared and blotted with anti-phosphotyrosine (D), and then anti-Cbl after stripping.
  • D anti-phosphotyrosine
  • Figure 14 shows the immunoprecipitation ofthe Lypl, ZAP-70 and FYN proteins from (a) COS-7 monkey epithelial cell line or (B) the 293T human epithelial cell line, the cell lines being transfected with the cDNA for Lypl, ZAP-70 or Fyn in the eucaryotic expression vector pcDNA3.
  • Western blotting was performed with anti-phosphotyrosine antibodies and chemiluminescent detection reagents.
  • Lypl co-transfection resulted in a reduction in Zap-70 phosphorylation while Fyn was unaffected.
  • Figure 15 shows shows the immunoprecipitation ofthe Lypl, Jak3, Syk and Fyn proteins from COS-7 monkey epithelial cell line, the cell line being transfected with the cDNA for Lypl, Jak3, Syk, or Fyn in the eucaryotic expression vector pcDNA3.
  • Syk was also co-transfected with Lyp-N, a catalytically inactive form of Lypl .
  • Western blotting was performed with anti-phosphotyrosine antibodies and chemiluminescent detection reagents.
  • Lypl reduced the tyrosine phosphorylation of Jak3 (C) while having little effect on Syk (D). No effect was seen when Syk was cotransfected with Lyp-N (D).
  • Lyp A novel intracellular human phosphatase gene, Lyp, has been isolated and identified. Lyp is predominantly expressed in the lymphoid cell lineages. Lyp is a member ofthe PEST phosphatase family and is most closely related to the murine phosphatase Z70PEP. Hydropathy analysis has indicated that Lyp contains no obvious signal sequence or hydrophobic segments and thus apparently encodes a cytoplasmic protein containing a single catalytic phosphatase domain. The non- catalytic portions ofthe phosphatase contain areas of high proline, glutamic acid, serine and threonine content (PEST sequences). There also appear to be other formally recognized functional domain structures within the remainder ofthe protein.
  • a short linear amino acid sequence also found in PEP has been demonstrated to bind the murine phosphatase to the cytoplasmic tyrosine kinase csk. There are otherwise several areas of high proline content which potentially may be recognized by SH3 domains.
  • Lyp Two forms of messenger RNA have been isolated for Lyp. The longer encodes the entire protein of 808 amino acids, Lypl, while the second shorter form arises from alternative splicing ofthe RNA and encodes Lyp2, which has 692 amino acids.
  • Lyp2 A 3.5kb intronic sequence of Lypl was found to contain an alternative exon, coding for the C-terminal 7 amino acids of Lyp2, and at least part of its 3' untranslated area (Fig.4).
  • the Lyp2 coding sequence consequently reads into this intronic sequence until a termination codon is encountered.
  • the two proteins have the first 685 amino acids in common, and the catalytic domain ofthe two forms is identical, as is most ofthe non-catalytic area.
  • the final 123 amino acids of Lypl are absent in Lyp2 and are replaced by seven unique residues. This is highly suggestive of major differences in the regulation ofthe activity ofthe two isoforms. Studies of expression ofthe proteins suggests that Lyp2 may only be present in resting lymphoid cells, while Lypl expression is increased upon activation.
  • Lypl and Lyp2 Two novel intracellular protein tyrosine phosphatase cDNA sequences have been isolated from a human thymus cDNA library; the first for Lypl (GenBank Accession No. AF 001846) and the second for its splice variant, Lyp2 (GenBank Accession No. AF001847).
  • the cDNA sequences for Lypl and Lyp2 (Sequence ID Nos:l and 3) are shown in Tables 1 and 3, respectively.
  • the corresponding amino acid sequences for Lypl and Lyp2 (Sequence ID Nos:2 and 4) are shown in Tables 2 and 4 respectively.
  • Lypl Sequence analysis of Lypl reveals significant homology with the murine phosphatase Z70PEP, an intracellular PTPase widely expressed in hematopoietic tissues (10). Lypl shares an overall amino acid sequence identity of 70% with Z70PEP (Fig. 2). While there is 89%> identity between the catalytic domain of Lypl and Z70PEP, significantly less homology is observed within the non catalytic portion (61%), which clearly contains a large area of unique sequence. Within this low homology area, Lypl contains four proline rich sequences which are also present in PEP (Fig. 2), forming putative PXXP and class II (XPPLPXR) SH3 domain binding motifs (10, 31).
  • the murine Z70PEP also possesses several consensus PEST sequences (hence its name [PEST]-domain Phosphatase)(10). PEST sequences contain an unusually high percentage of proline (P), glutamic/aspartic acid (E/D), serine (S), and threonine(T) residues.
  • PEST- FIND PC analysis software; Oxford Molecular Group, Oxford
  • Lypl contains a consensus sequence XS/TPXK/R ( 741 KTPGK 745 ) recognized by the p34 cdc2 kinase (41), a cell cycle regulatory kinase (42), suggesting that Lypl may be phosphorylated in a cell cycle dependent manner.
  • Lypl also contains four potential SH3 domain binding sites, compared to a single motif in Lyp2; suggesting the isoforms may interact with different sets of SH3 domains.
  • Lypl expression suggests that it is preferentially expressed in lymphoid cells (Fig. 5A,B,C), particularly in thymocytes and mature B and T cells. A low level of Lypl expression was also seen in tissues rich in lymphoid infiltrates, such as the small intestine and appendix.
  • the pattern of Lypl protein expression detected by antibodies in human hematopoietic cell lines correlated well with Lypl mRNA expression (Fig. 11). This pattern of expression suggests that Lypl may play a role in the regulation of aspects of both early and late states of T cell differentiation.
  • Lyp2 The mRNA expression of Lypl and its isoform, Lyp2, was differentiated by the use of more specific probes. While Lyp2 was present at lower levels than Lypl in all lymphoid tissues examined, Northern blot analysis indicated significant expression of Lyp2 in fetal liver tissue. Lymphoid mRNAs hybridized with a probe specific for the unique C-terminal of Lypl revealed the same pattern of expression seen in Northern blots obtained by using a cDNA fragment common to both Lyp forms (not shown).
  • Lyp2 expression in lymphoid cells is extremely low, below the threshold of detection of Northern blotting. This suggestion was confirmed by semi-quantitative PCR comparison of Lypl and Lyp2 expression. In thymocytes, the expression of Lypl was found to be 100 fold greater than that of Lyp2 (Fig. 8). Similar results were obtained from other lymphoid cells (not shown).
  • the 85 kD protein is believed to be Lyp2 on the basis of its apparent molecular weight and the fact that both Lyp antibodies can recognize it. This finding suggests that Lyp2 may play an important role in resting cells, since thymocytes, tonsil T cells and lymphoid cell lines, which are activated cells, do not express the protein.
  • Anti-CD3 stimulation of thymocytes was found to induce the association of a 116 kD phosphorylated protein with Lyp 1.
  • Western blotting of Lyp immunoprecipitates identified the phosphorylated band to be the proto-oncogene c- Cbl.
  • cbl was found to be constitutively associated with Lypl . From previous studies it is known that Cbl is heavily tyrosine phosphorylated following TCR stimulation (58) and can associate with the Syk and ZAP tyrosine kinases, negatively regulating their activities (59-63).
  • Cbl is an adaptor protein which associates with numerous protein tyrosine kinases
  • Lyp may play a role in the regulation of these proteins (62).
  • ENY the Cbl PTB domain consensus binding motif
  • D(N/D)XpY the Cbl PTB domain consensus binding motif
  • a multiple SH3 domain adaptor protein such as Grb2 may serve to link Lyp and Cbl.
  • Lypl is constitutively associated in T cells with the proto- oncogene c-Cbl, a protein which is recognized to be important in the regulation ofthe Zap family kinases.
  • Lyp is constitutively bound to the Syk kinase and inducibly binds a number of phosphorylated proteins after stimulation ofthe cell through the B cell receptor.
  • Lypl reduces phosphorylation of, and thereby reduces the activity of, the T cell tyrosine kinase, Zap-70, while it has little effect upon the closely related Syk kinase, possibly even elevating its activity.
  • a similar selective activity is seen with members ofthe src family of kinases. Lypl strongly down-regulates Lyn kinase activity, while Fyn function is unaffected. The ability to turn off Zap-70 and Lyn strongly suggests a role for Lyp in regulating antigen receptor signalling, as these kinases are central to the signal transduction cascades. Overexpression of Lypl in T cells appears to interfere with activation ofthe Zap-70 kinase through the T cell receptor.
  • Lypl also reduced phosphorylation of, and thereby reduced the activity of, the cytoplasmic Jak3 tyrosine kinase and prevented it from phosphorylating the insulin receptor substrate proteins.
  • Lyp is also in a position to regulate signal transduction through a number ofthe cytokine receptors. Activation of Jak kinases appears to be a primary event after ligand binding to cytokine receptors and absolutely necessary for signal transduction.
  • Zap 70 protein T lymphocytes lacking functional Zap 70 protein do not respond satisfactorily to antigenic stimulation and since antigenic stimulation is required for normal T cell maturation, such lymphocytes fail to mature properly (Arpaia et al., (1994), Cell, v. 76, pp. 947-958; Perlmutter, R., (1994), Nature, v. 370, p. 249).
  • the importance of Zap 70 kinase in T cell antigen receptor signalling also means that if one can interfere with or prevent Zap 70 kinase activity, one can modulate T cell activation and proliferation in situations where T cell activation and proliferation is excessive or undesired.
  • Stimulators or activators of Lypl could be used as drugs which, by reducing Zap70 activity, could reduce or block T cell activation.
  • Lypl could be used to control T cell activation.
  • T cells also depends on IL2 receptor signal transduction, which involves Jak3 kinase activation.
  • Jak3 kinase activation involves Jak3 kinase activation.
  • Lypl activity will reduce or prevent T cell proliferation by reducing Jak3 kinase activity.
  • Over-expression of, or stimulation ofthe activity of, Lypl therefore provides a two-locus control of T cell activation and proliferation, (1) by blocking initial signals transmitted via the T cell receptor and (2) by blocking progression of T cell proliferation by blocking IL2-mediated responses.
  • Lypl This selective effect of Lypl renders it an ideal target for candidate immunosuppressive drugs which can be used, for example, in organ or tissue graft rejection, graft versus host disease, and autoimmune diseases, including diabetes, rheumatic diseases, multiple sclerosis and other nervous system diseases.
  • Jak3 kinase activity is of crucial importance in the proliferation of lymphoma cells. Reducing or blocking the activity of Jak3 kinase and Zap70 kinase by manipulating the activity of Lypl, for example by causing its over- expression, provides a powerful means of reducing or preventing the growth of T cell lymphomas.
  • Zap70 and Jak3 kinase activities are important in thymocyte differentiation and control of these kinase activities by manipulation of Lypl activity provides a method for controlling thymocyte differentiation.
  • the Lyp gene was found to be localized to chromosome lpl3 (Fig. 3). This region is of particular interest because it is a common site of chromosomal rearrangement in both solid and hematopoietic cancers (47, 48).
  • One such chromosomal rearrangement is a frequent alteration in the lpl3 region in chromosomally aberrant clones isolated from both patients with Hodgkin's (49, 50) and non Hodgkin's (51) lymphomas.
  • PTPases may act as tumour suppression genes (2, 52). This suggests an association between an abnormality ofthe lpl3 locus in these patients and an alteration of Lyp and thus an involvement of Lyp in tumorigenesis.
  • this invention provides isolated polynucleotides corresponding to the nucleotide sequences encoding the human Lypl and Lyp2 proteins.
  • the polynucleotides may be in the form of DNA, genomic DNA, cDNA or mRNA or an anti-sense DNA corresponding to a disclosed sequence.
  • portions ofthe Lyp sequences useful as probes and PCR primers or for encoding fragments, functional domains or antigenic determinants of Lyp proteins.
  • Lyp genes or cDNAs which are allelic variants ofthe disclosed Lyp sequences, using standard hybridization screening or PCR techniques.
  • the invention provides portions ofthe disclosed nucleotide sequences comprising about 10 consecutive nucleotides (e.g. for use as PCR primers) to nearly the complete disclosed nucleotide sequences.
  • the invention provides isolated nucleotide sequences comprising sequences corresponding to at least 10, preferably 15 and more preferably at least 20 consecutive nucleotides of the Lyp gene as disclosed or enabled herein or their complements.
  • the isolated polynucleotides ofthe invention include any ofthe above described nucleotide sequences included in a vector.
  • the invention provides an isolated polynucleotide which encodes a Lyp protein having an amino acid sequence of greater than 70% overall identity to the amino acid sequence of Table 2 or 4.
  • the invention also includes polynucleotides which are complementary to the disclosed nucleotide sequences, polynucleotides which hybridize to these sequences under high stringency and degeneracy equivalents of these sequences.
  • the invention also includes an isolated polynucleotide which encodes a Lyp protein having an amino acid sequence with at least 80% overall identity, preferably at least 90% overall identity to the amino acid sequence of Table 2 or 4.
  • This invention provides Lyp proteins and a method for producing such proteins.
  • a Lyp protein has an amino acid sequence having greater than 70% overall identity to the amino acid sequence of Lypl (Table 2, Sequence ID No:2).
  • a Lyp protein has an amino acid sequence having at least 80% overall identity, preferably at least 90%, to the amino acid sequence of Lypl.
  • the invention provides substantially purified Lyp proteins, including the proteins of Table 2 (Lypl) and Table 4 (Lyp2).
  • the invention includes analogs of the disclosed protein sequences, having conservative amino acid substitutions therein.
  • the invention also includes fragments of the disclosed protein sequences, such as peptides comprising at least 5, preferably 10 and more preferably 20 consecutive amino acids of the disclosed protein sequences.
  • the invention further provides polypeptides comprising at least one functional domain or at least one antigenic determinant of a Lyp protein.
  • the invention enables the production of Lyp proteins, such as human Lyp 1 and Lyp 2.
  • Lyp proteins may be produced by culturing a host cell transformed with a DNA sequence encoding a selected Lyp protein.
  • the DNA sequence is operatively linked to an expression control sequence in a recombinant vector so that the protein may be expressed.
  • Host cells which may be transfected with the vectors of the invention may be selected from the group consisting of E. coli, Pseudomonas, Bacillus subtillus, or other bacilli, yeasts, fungi, insect cells or mammalian cells including human cells.
  • the vector may be delivered to the cells by a suitable vehicle.
  • suitable vehicles including vaccinia virus, adenovirus, retrovirus, Herpes simplex virus and other vector systems known to those of skill in the art.
  • a Lyp protein may also be recombinantly expressed as a fusion protein.
  • the Lyp cDNA sequence is inserted into a vector which contains a nucleotide sequence encoding another peptide (e.g. GST-glutathione succinyl transferase).
  • the fusion protein is expressed and recovered from prokaryotic (e.g. bacterial or baculovirus) or eukaryotic cells.
  • the fusion protein can then be purified by affinity chromatography based upon the fusion vector sequence and the Lyp protein obtained by enzymatic cleavage ofthe fusion protein.
  • the protein may also be produced by conventional chemical synthetic methods, as understood by those skilled in the art.
  • Lyp proteins may also be isolated from cells or tissues, including mammalian cells or tissues, in which the protein is normally expressed.
  • the protein may be purified by conventional purification methods known to those in the art, such as chromatography methods, high performance liquid chromatography methods or precipitation.
  • an anti-Lyp antibody may be used to isolate a Lyp protein which is then purified by standard methods.
  • E. coli can be used using the T7 RNA polymerase/promoter system using two plasmids or by labeling of plasmid-encoded proteins, or by expression by infection with Ml 3 Phage mGPI-2.
  • E coli vectors can also be used with Phage lamba regulatory sequences, by fusion protein vectors (eg. lacZ and trpE), by maltose-binding protein fusions, and by glutathione-S-transferase fusion proteins.
  • the Lypl or Lyp2 protein can be expressed in insect cells using baculoviral vectors, or in mammalian cells using vaccinia virus.
  • the cDNA sequence may be ligated to heterologous promoters, such as the simian virus (SV40) promoter in the pSV2 vector and introduced into cells, such as COS cells to achieve transient or long-term expression.
  • SV40 simian virus
  • the stable integration ofthe chimeric gene construct may be maintained in mammalian cells by biochemical selection, such as neomycin and mycophoenolic acid.
  • the Lyp DNA sequence can be altered using procedures such as restriction enzyme digestion, fill-in with DNA polymerase, deletion by exonuclease, extension by terminal deoxynucleotide transferase, ligation of synthetic or cloned DNA sequences, site-directed sequence alteration with the use of specific oligonucleotides together with PCR.
  • the cDNA sequence or portions thereof, or a mini gene consisting of a cDNA with an intron and its own promoter is introduced into eukaryotic expression vectors by conventional techniques. These vectors permit the transcription of the cDNA in eukaryotic cells by providing regulatory sequences that initiate and enhance the transcription of the cDNA and ensure its proper splicing and polyadenylation.
  • the endogenous Lyp gene promoter can also be used. Different promoters within vectors have different activities which alters the level of expression ofthe cDNA. In addition, certain promoters can also modulate function such as the glucocorticoid-responsive promoter from the mouse mammary tumor virus.
  • Some of the vectors listed contain selectable markers or neo bacterial genes that permit isolation of cells by chemical selection. Stable long-term vectors can be maintained in cells as episomal, freely replicating entities by using regulatory elements of viruses. Cell lines can also be produced which have integrated the vector into the genomic DNA. In this manner, the gene product is produced on a continuous basis.
  • Vectors are introduced into recipient cells by various methods including calcium phosphate, strontium phosphate, electroporation, lipofection, DEAE dextran, microinjection, or by protoplast fusion.
  • the cDNA can be introduced by infection using viral vectors.
  • Eukaryotic expression systems can be used for many studies of the Lyp gene and gene product(s) including determination of proper expression and post- translational modifications for full biological activity, identifying regulatory elements located in the 5' region of the Lyp gene and their role in tissue regulation of protein expression, production of large amounts ofthe normal and mutant protein for isolation and purification, to use cells expressing the Lypl or Lyp2 protein as a functional assay system for antibodies generated against the protein or to test effectiveness of pharmacological agents, or as a component of a signal transduction system, to study the function of the normal complete protein, specific portions of the protein, or of naturally occurring and artificially produced mutant proteins.
  • the expression vectors containing the Lypl or Lyp2 cDNA sequence or portions thereof can be introduced into a variety of mammalian cells from other species or into non-mammalian cells.
  • the recombinant cloning vector comprises the selected DNA of the DNA sequences of this invention for expression in a suitable host.
  • the DNA is operatively linked in the vector to an expression control sequence in the recombinant DNA molecule so that Lypl or Lyp2 protein can be expressed.
  • the expression control sequence may be selected from the group consisting of sequences that control the expression of genes of prokaryotic or eukaryotic cells and their viruses and combinations thereof.
  • the expression control sequence may be selected from the group consisting of the lac system, the tip system, the tac system, the trc system, major operator and promoter regions of phage lambda, the control region of the fd coat protein, early and late promoters of SV40, promoters derived from polyoma, adenovirus, retrovirus, baculovirus, simian virus, 3-phosphoglycerate kinase promoter, yeast acid phosphatase promoters, yeast alpha-mating factors and combinations thereof.
  • Lyp gene expression in heterologous cell systems may also be used to demonstrate structure-function relationships as well as to provide cell lines for the purposes of drug screening.
  • Ligating the Lyp DNA sequence into a plasmid expression vector to transfect cells is a useful method to test the proteins influence on various cellular biochemical parameters including the identification of substrates as well as activators and inhibitors of the phosphatase.
  • Plasmid expression vectors containing either the entire coding sequence for Lypl or Lyp2, or for portions thereof, can be used in in vitro mutagenesis experiments which will identify portions of the protein crucial for regulatory function.
  • the DNA sequence can be manipulated in studies to understand the expression of the gene and its product.
  • the changes in the sequence may or may not alter the expression pattern in terms of relative quantities, tissue-specificity and functional properties.
  • the present invention enables antibodies which bind selectively to a Lyp protein or to an antigenic determinant of a Lyp protein.
  • an antibody is said to "bind selectively" to a target if the antibody recognises and binds to the target of interest but does not substantially recognise and bind to other molecules in a sample which includes the target of interest.
  • Antibodies to an Lyp protein also allow for the use of immunocytochemistry and immunofluorescence techniques in which the proteins can be visualized directly in cells and tissues. This is useful to establish the subcellular location of the protein and the tissue specificity ofthe protein.
  • Antibodies to an Lyp protein may also be used to inhibit the protein's activity, where reduced activity is desired.
  • fusion proteins containing, for example, defined portions or all of the Lypl or Lyp2 protein or specific Lypl or Lyp2 generated mutants can be synthesized in bacteria by expression of corresponding DNA sequences in a suitable cloning vehicle.
  • the protein can then be purified, coupled to a carrier protein and mixed with Freund's adjuvant (to help stimulate the antigenic response by the rabbits) and injected into rabbits or other laboratory animals.
  • protein can be isolated from cultured cells expressing the protein. Following booster injections at bi-weekly intervals, the rabbits or other laboratory animals are then bled and the sera isolated.
  • the sera can be used directly or purified prior to use, by affinity chromatography.
  • the sera can then be used to probe protein extracts run on a polyacrylamide gel to identify the Lypl or Lyp2 protein or mutant protein.
  • synthetic peptides can be made to the antigenic portions of these proteins and used to innoculate the animals.
  • mice actively expressing the protein are cultured or isolated from tissues and the cell extracts isolated.
  • the extracts or recombinant protein extracts, containing the Lypl or Lyp2 protein, are injected in Freund's adjuvant into mice. After being injected 9 times over a three week period, the mice spleens are removed and resuspended in phosphate buffered saline (PBS).
  • PBS phosphate buffered saline
  • the spleen cells serve as a source of lymphocytes, some of which are producing antibody of the appropriate specificity.
  • tissue culture wells in the presence of a selective agent such as HAT.
  • the wells are then screened to identify those containing cells making useful antibody by ELISA. These are then freshly plated. After a period of growth, these wells are again screened to identify antibody-producing cells.
  • Several cloning procedures are carried out until over 90% of the wells contain single clones which are positive for antibody production. From this procedure a stable line of clones is established which produce the antibody.
  • the monoclonal antibody can then be purified by affinity chromatography using Protein A Sepharose. Suitable methods for antibody production may be found in standard texts such as Antibody Engineering, 2 nd Edition, Barreback, E.D., Oxford University Press (1995).
  • the invention provides non-human transgenic animals and methods for the production of non-human transgenic animals which afford models for further study of Lyp proteins and tools for screening candidate compounds as potential therapeutic agents.
  • knock-out animals such as mice may be produced with deletion of the Lyp gene. These animals may be examined for phenotypic changes and used to screen candidate compounds for effectiveness to reverse these changes.
  • transgenic mice In general, techniques of generating transgenic animals are widely accepted and practiced. A laboratory manual on the manipulation of the mouse embryo, for example, is available, detailing standard laboratory techniques for the production of transgenic mice (41).
  • a wild type human Lyp gene and/or a humanized murine gene could be inserted into the animals genome by homologous recombination. It is also possible to insert a mutant (single or multiple) human gene as genomic or minigene construct using wild type or mutant or artificial promoter elements. More commonly, and most preferred in the present invention, knock-out of the endogenous murine genes may be accomplished by the insertion of artificially modified fragments of the endogenous gene by homologous recombination. The modifications include insertion of mutant stop codons, the deletion of DNA sequences, or the inclusion of recombination elements (lox p sites) recognized by enzymes such as Cre recombinase.
  • embryonic stem cells heterozygous for a knockout mutation in a gene of interest ie. Lyp gene
  • a marker gene eg. coat colour
  • the early embryos then are implanted into a pseudopregnant female. Some of the resulting progeny are chimeras. Chimeric mice then are backcrossed. Intercrossing will eventually produce individuals homozygous for the disrupted allele that is, knockout mice.
  • Lyp mouse gene chemical or x-ray mutagenesis of mouse gametes, followed by fertilization, can be applied. Heterozygous offspring can then be identified by Southern blotting to demonstrate loss of one allele by dosage, or failure to inherit one parental allele using RFLP markers.
  • a mutant or normal version of the human Lyp gene can be inserted into a mouse germ line using standard techniques of oocyte microinjection or transfection or microinjection into stem cells.
  • homologous recombination using embryonic stem cells may be applied.
  • a mutant or normal Lyp gene can be inserted into the pronucleus of a just-fertilized mouse oocyte. This oocyte is then reimplanted into a pseudo-pregnant foster mother. The liveborn mice can then be screened for integrants using analysis of tail DNA for the presence of human Lyp gene sequences.
  • the transgene can be either a complete genomic sequence injected as a YAC or chromosome fragment, a cDNA with either the natural promoter or a heterologous promoter, or a minigene containing all of the coding region and other elements found to be necessary for optimum expression.
  • Retroviral infection of early embryos can also be done to insert the human Lyp gene.
  • the human Lyp gene is inserted into a retroviral vector which is used to directly infect mouse embryos during the early stages of development to generate a chimera, some of which will lead to germline transmission.
  • Homologous recombination using stem cells allows for the screening of gene transfer cells to identify the rare homologous recombination events. Once identified, these can be used to generate chimeras by injection of mouse blastocysts, and a proportion of the resulting mice will show germline transmission from the recombinant line.
  • This methodology is especially useful if inactivation of the human Lyp gene is desired.
  • inactivation of the Lyp gene can be done by designing a DNA fragment which contains sequences from a Lyp exon flanking a selectable marker.
  • Homologous recombination leads to the insertion of the marker sequences in the middle of an exon, inactivating the Lyp gene. DNA analysis of individual clones can then be used to recognize the homologous recombination events.
  • the knowledge of the human Lyp sequence provides for screening for diseases involving abnormally activated or inactivated Lypl or Lyp2 in which the activity defect is due to a mutant Lyp gene.
  • unregulated Jak 3 kinase leads to tumorigenesis (Schwaller, J. et al., (1998), EMBO J., v. 17, p. 5321-33; Lacronique et al, (1997), Science, v. 278, p. 1309-12; Peeters et al., (1997), Blood, v. 90, p. 2535-40).
  • a loss of Lyp activity for example through a null mutation of Lyp, may lead to tumour formation, for example leukemia.
  • Other defects associated with loss of Lyp function may include autoimmune disorders such as rheumatoid arthritis.
  • Genomic DNA used for the diagnosis may be obtained from body cells, such as those present in the blood, tissue biopsy, surgical specimen, or autopsy material.
  • the DNA may be isolated and used directly for detection of a specific sequence or may be PCR amplified prior to analysis.
  • RNA or cDNA may also be used.
  • direct DNA sequencing, restriction enzyme digest, RNase protection, chemical cleavage, and ligase-mediated detection are all methods which can be utilized.
  • Oligonucleotides specific to mutant sequences can be chemically synthesized and labelled radioactively with isotopes, or non- radioactively using biotin tags, and hybridized to individual DNA samples immobilized on membranes or other solid-supports by dot-blot or transfer from gels after electrophoresis. The presence or absence of these mutant sequences is then visualized using methods such as autoradiography, fluorometry, or colorimetric reaction. Suitable PCR primers can be generated which are useful for example in amplifying portions ofthe subject sequence containing identified mutations.
  • Direct DNA sequencing reveals sequence differences between normal and mutant Lyp DNA.
  • Cloned DNA segments may be used as probes to detect specific DNA segments.
  • PCR can be used to enhance the sensitivity of this method.
  • PCR is an enzymatic amplification directed by sequence-specific primers, and involves repeated cycles of heat denaturation of the DNA, annealing of the complementary primers and extension ofthe annealed primer with a DNA polymerase. This results in an exponential increase ofthe target DNA.
  • Other nucleotide sequence amplification techniques may be used, such as ligation-mediated PCR, anchored PCR and enzymatic amplification as would be understood by those skilled in the art.
  • Sequence alterations may also generate fortuitous restriction enzyme recognition sites which are revealed by the use of appropriate enzyme digestion followed by gel-blot hybridization. DNA fragments carrying the site (normal or mutant) are detected by their increase or reduction in size, or by the increase or decrease of corresponding restriction fragment numbers. Genomic DNA samples may also be amplified by PCR prior to treatment with the appropriate restriction enzyme and the fragments of different sizes are visualized under UV light in the presence of ethidium bromide after gel electrophoresis.
  • Genetic testing based on DNA sequence differences may be achieved by detection of alteration in electrophoretic mobility of DNA fragments in gels. Small sequence deletions and insertions can be visualized by high resolution gel electrophoresis. Small deletions may also be detected as changes in the migration pattern of DNA heteroduplexes in non-denaturing gel electrophoresis. Alternatively, a single base substitution mutation may be detected based on differential primer length in PCR. The PCR products of the normal and mutant gene could be differentially detected in acrylamide gels.
  • Nuclease protection assays (SI or ligase-mediated) also reveal sequence changes at specific locations.
  • ASO to confirm or detect a polymorphism restriction mapping changes ligated PCR, ASO, REF-SSCP and SSCP may be used. Both REF-SSCP and SSCP are mobility shift assays which are based upon the change in conformation due to mutations.
  • DNA fragments may also be visualized by methods in which the individual DNA samples are not immobilized on membranes.
  • the probe and target sequences may be in solution or the probe sequence may be immobilized.
  • Autoradiography, radioactive decay, spectrophotometry, and fiuorometry may also be used to identify specific individual genotypes.
  • the portion of the DNA segment that is informative for a mutation can be amplified using PCR.
  • the DNA segment immediately surrounding a specific mutation acquired from peripheral blood or other tissue samples from an individual can be screened using constructed oligonucleotide primers. This region would then be amplied by PCR, the products separated by electrophoresis, and transferred to membrane. Labelled probes are then hybridized to the DNA fragments and autoradiography performed.
  • the invention enables a method for screening candidate compounds for their ability to increase or decrease the phosphatase activity of a Lyp protein.
  • the method comprises providing an assay system for assaying Lyp phosphatase activity, assaying the phosphatase activity in the presence or absence of the candidate compound and determining whether the compound has increased or decreased the control phosphatase activity.
  • the effect of a candidate compound on Lyp phosphatase activity may be determined, for example, in an assay system such as that described in Example 7 herein.
  • the invention enables a method for screening candidate compounds for their ability to increase or decrease expression of a Lyp protein.
  • the method comprises contacting a cell with a candidate compound, wherein the cell includes a regulatory region of a Lyp gene operably joined to a coding region, and detecting a change in expression ofthe coding region.
  • the present invention enables culture systems in which cell lines which express the Lyp gene, and thus Lypl and/or Lyp2 protein products, are incubated with candidate compounds to test their effects on Lyp expression.
  • Such culture systems can be used to identify compounds which upregulate or downregulate Lyp expression or its function through the interaction with other proteins.
  • Such compounds can be selected from protein compounds, chemicals and various drugs which are added to the culture medium. After a period of incubation in the presence of a selected test compound(s), the expression of Lyp can be examined by quantifying the levels of Lyp mRNA using standard Northern blotting procedure as described in the examples included herein to determine any changes in expression as a result ofthe test compound. Cell lines transfected with constructs expressing Lyp can also be used to test the function of compounds developed to modify the protein expression. In addition, transformed cell lines expressing a normal Lyp protein could be mutagenized by the use of mutagenizing agents to produce an altered phenotype in which the role of mutated Lyp can be studied in order to study structure/function relationships ofthe protein products and their physiological effects.
  • Lyp protein products may be assessed through phosphorylation assays as are described herein in the examples. Such assays would identify the role of certain compounds on Lyp function and subsequent intracellular protein interaction and physiological effect.
  • Lypl down-regulates T cell Zap-70 tyrosine kinase activity and thus activation of T cells. Lypl is also demonstrated to down-regulate Lyn kinase activity. This strongly suggests a role for Lypl in the regulation of antigen receptor signalling. Therefore, these pathways could be further elucidated by the identification of drugs/agents which alter Lypl and thus such antigen receptor signalling and further downstream physiological effects.
  • Such cell culture assays may elucidate the specific nature of Lypl in the regulation of the Zap and Lyn family kinases. Incubating cell cultures expressing Lyp with agents that affect phosphorylation may also help to elucidate the involvement of other down stream proteins such as DNA-binding proteins and transcription factors in transcription regulation.
  • cell culture assays as described herein can help to identify candidate compounds to inhibit the effect of Lyp on Jak3 tyrosine kinase activity or modify its effect and thus down-stream intracellular signalling and physiological effects. This may help to identify compounds which regulate activation of cytokine receptors which act through the Jak3 tyrosine kinase signal transduction cascade.
  • immunosuppressive agents for example by reducing or preventing T cell activation.
  • immunosuppressive agents can be employed to treat conditions requiring immunosuppression, including autoimmune diseases such as rheumatic diseases, diabetes, and multiple sclerosis and transplant situations, where suppression of graft rejection or graft versus host reactions are required.
  • This invention enables a method for modulating signalling mediated by the T cell receptor, the method comprising administering to a T cell an agent which increases Lyp phosphatase activity or increases Lyp expression in the T cell.
  • the invention further enables a method for reducing or preventing T cell activation and/or proliferation , the method comprising administering to the T cell an agent which increases Lyp phosphatase activity or increases Lyp expression in the T cell.
  • the invention further enables a method for treating a disorder which requires immunosuppression, the method comprising administering to the subject in need of treatment an immunosuppression-effective amount of an agent which increases Lyp phosphatase activity or increases Lyp expression.
  • the invention enables a method for treating lymphoma in a subject, the method comprising administering to the subject an agent which increases Lyp phosphatase activity or increases Lyp expression in an amount effective to reduce or prevent lymphoma cell proliferation.
  • the invention further provides methods for preventing or treating disorders characterised by an abnormality in the T cell receptor signalling pathway or the IL2- mediated signalling pathway, comprising modulating signalling by administration of an agent which increases or decreases Lyp phosphatase activity or Lyp expression.
  • T cell receptor signalling modulation is useful in disorders such as autoimmune diseases and in transplant situations, as discussed elsewhere herein.
  • the present invention enables gene therapy as a potential therapeutic approach, in which normal copies of the Lyp gene are introduced into patients to successfully code for normal Lypl or Lyp2 protein in several different affected cell types. Mutated copies of the Lyp gene in which the protein product is inactivated can also be introduced into patients.
  • Retroviral vectors can be used for somatic cell gene therapy especially because of their high efficiency of infection and stable integration and expression.
  • the targeted cells however must be able to divide and the expression of the levels of normal protein should be high.
  • the full length Lyp gene can be cloned into a retroviral vector and driven from its endogenous promoter or from the retroviral long terminal repeat or from a promoter specific for the target cell type of interest (such as lymphoid cells).
  • viral vectors which can be used include adeno-associated virus, vaccinia virus, bovine papilloma virus, or a herpesvirus such as Epstein-Barr virus.
  • Gene transfer could also be achieved using non-viral means requiring infection in vitro. This would include calcium phosphate, DEAE dextran, electroporation, and protoplast fusion. Liposomes may also be potentially beneficial for delivery of DNA into a cell. Although these methods are available, many of these are lower efficiency.
  • Transplantation of normal genes or mutated genes which code for an inactive Lypl or Lyp2 into a targeted affected area ofthe patient can also be useful therapy for any disorder in which Lyp activity is deficient.
  • a Lyp gene is transferred into a cultivatable cell type such as lymphoid cells, either exogenously or endogenously to the patient.
  • the transformed cells are then injected into the patient.
  • the invention also provides a method for reversing a transformed phenotype resulting from the excess expression of the Lyp human gene sequence, and/or hyperactivation of a Lypl or Lyp2 protein product.
  • Antisense based strategies can be employed to explore gene function, inhibit gene function and as a basis for therapeutic drug design. The principle is based on the hypothesis that sequence specific suppression of gene expression can be achieved by intracellular hybridization between mRNA and a complementary anti-sense species. It is possible to synthesize anti-sense strand nucleotides that bind the sense strand of RNA or DNA with a high degree of specificity. The formation of a hybrid RNA duplex may interfere with the processing/transport/translation and/or stability of a target mRNA.
  • Hybridization is required for an antisense effect to occur.
  • Antisense effects have been described using a variety of approaches including the use of antisense oligonucleotides, injection of antisense RNA, DNA and transfection of antisense RNA expression vectors.
  • Therapeutic antisense nucleotides can be made as oligonucleotides or expressed nucleotides. Oligonucleotides are short single strands of DNA which are usually 15 to 20 nucleic acid bases long. Expressed nucleotides are made by an expression vector such as an adenoviral, retroviral or plasmid vector. The vector is administered to the cells in culture, or to a patient, whose cells then make the antisense nucleotide. Expression vectors can be designed to produce antisense RNA, which can vary in length from a few dozen bases to several thousand.
  • Antisense effects can be induced by control (sense) sequences.
  • the extent of phenotypic changes are highly variable. Phenotypic effects induced by antisense are based on changes in criteria such as biological endpoints, protein levels, protein activation measurement and target mRNA levels.
  • Multidrug resistance is a useful model for the study of molecular events associated with phenotypic changes due to antisense effects since the MDR phenotype can be established by expression of a single gene mdrl (MDR gene) encoding P- glycoprotein (a 170 kDa membrane glycoprotein, ATP-dependent efflux pump).
  • MDR gene mdrl
  • mammalian cells in which the Lyp human cDNA has been transfected and which express an abnormal phenotype can be additionally transfected with anti-sense Lyp (Lypl or Lyp2) nucleotide DNA sequences which hybridize to the Lyp gene in order to inhibit the transcription ofthe gene and reverse or reduce the abnormal phenotype.
  • portions ofthe Lyp gene can be targeted with an anti-sense Lyp sequence specific for the kinase domains or the unique amino terminal sequence which may be responsible for the malignant phenotype.
  • Expression vectors can be used as a model for anti-sense gene therapy to target the Lyp which is expressed in abnormal cells. In this manner abnormal cells and tissues can be targeted while allowing healthy cells to survive. This may prove to be an effective treatment for cell abnormalities induced by Lypl or Lyp2.
  • Immunotherapy is also possible for the treatment of diseases associated with excess Lyp activity.
  • Antibodies can be raised to a hyperactive Lypl or Lyp2 protein (or portion thereof) and then be administered to bind or block the abnormal protein and its deliterious effects. Simultaneously, expression of the normal protein product could be encouraged.
  • Administration could be in the form of a one time immunogenic preparation or vaccine immunization.
  • An immunogenic composition may be prepared as injectables, as liquid solutions or emulsions.
  • the Lyp protein may be mixed with pharmaceutically acceptable excipients compatible with the protein. Such excipients may include water, saline, dextrose, glycerol, ethanol and combinations thereof.
  • the immunogenic composition and vaccine may further contain auxiliarry substances such as emulsifying agents or adjuvants to enhance effectiveness. Immunogenic compositions and vaccines may be administered parenterally by injection subcutaneously or intramuscularly.
  • the immunogenic preparations and vaccines are administered in such amount as will be therapeutically effective, protective and immunogenic. Dosage depends on the route of administration and will vary according to the size ofthe host.
  • Thymuses were obtained from children undergoing open heart surgery. Mononuclear cells were isolated by Ficoll-Hypaque gradient. Adherent cells were removed by incubation to plastic dishes for 60 minutes at 37°C. The resulting thymocytes are typically >95% CD3+.
  • a PCT-based approach was used with degenerate oligonucleotides directed at conserved regions ofthe PTPase catalytic domain.
  • a fragment of ⁇ 400bp was amplified from thymocyte cDNA and identified PCR amplified clones corresponding to seven different phosphatases.
  • Six clones were identical to previously isolated human phosphatases:PTP-PEST, 24 PTP1B, 25 TCPTP, 26 HPTP ⁇ , 6 CD45 and PTPMEG2.
  • a seventh clone had no human homologue but was 90% homologous to the murine phosphatase Z70PEP.
  • This clone was used to screen a human thymocyte cDNA library.
  • the first screening isolated two overlapping clones, PI and P2 (Fig.l).
  • Clone P2 was used to isolate a further three overlapping clones P3-P5 from the cDNA library.
  • Assembly ofthe five overlapping clones revealed a single cDNA of 2300bp containing an open reading frame (ORF) of 2076bp, predicting a protein of 692 amino acids.
  • ORF open reading frame
  • the sequence surrounding the putative ATG/methionine start codon contained a purine (A) at position -3 and G at +4, both regarded as important criteria for an eucaryotic initiation site.
  • the N-terminal region ofthe amino acid sequence contained a single PTPase catalytic domain characterized by the conserved sequence motif (I/V)HCXXGXXRS/T. This sequence, thought to form the phosphate binding pocket for substrate, is found in all PTPases and is essential for their enzymatic activity.
  • a single kb clone was isolated (P6, Fig. 1), with 200bp of its 5'-end overlapping nucleotides 1950-2055 ofthe complete cDNA previously isolated. However this was followed by an alternative 700bp, coding for an ORF totalling 2424bp.
  • Lypl is an alternative spliced isoform of Lypl.
  • PTP2 GCGAATTCCCIACICCIGC(A/G)CT(G/A)CA(G/A)TG [antisense, SEQ. ID NO:
  • PTPase catalytic domains PTPase catalytic domains, XDYINA and HCSAG/VG respectively.
  • PCR was performed as follows: five cycles of 60sec. at 94 ° C, 30 sec. at 37 ° C and 60 sec. at 72 ° C , and a further 25 cycles with an annealing temperature of 45 ° C. Fragments of approximately 400bp were isolated, cloned and sequenced.
  • oligo-dT derived ⁇ gtlO cDNA library from human thymocytes was screened with a [ 32 P] labelled 430bp Lypl fragment obtained by PCR. ⁇ Plaques were transferred to ICN Biotrans nylon filters and screened by hybridization at 65 ° C in 5 x SSC, 5 x Denhart's solution, 0.1%SDS (22). Phage DNA was prepared from positive plaques, cDNA inserts were excised, subcloned into pUC-19, and sequenced. To obtain the complete Lypl cDNA, secondary and tertiary library screenings were performed with the 1.3kb and 0.6kb partial cDNA clones isolated in the first screening (Fig. 1) . One clone (P5) from the second screening was found to contain the carboxyterminal sequence ofthe spliced form of Lypl (Lyp2).
  • Example 2 Lyp2 production by alternative RNA splicing ofthe Lypl message.
  • oligonucleotide 1 corresponded to the common nucleotides 2076-2097 of Lypl and Lyp2 (Table 1 and 2), oligonucleotide 2 to Lyp2 untranslated area adjacent to the stop codon (nucleotides 2150-2168), and olignucleotide 3 to Lypl sequence immediately downstream of primer 1 (nucleotides 2098-2120) (Fig 4A).
  • Fig 4B The resultant PCR products are shown in Fig 4B.
  • PCR amplification with primers 1 and 3 created an approximately 3.5kb DNA fragment, suggesting the presence of an intron between the primers.
  • primers 1 and 2 resulted in a much smaller fragment of lOObp, the size expected from Lyp2 cDNA sequence.
  • the 5' end sequence ofthe 3.5kb fragment was found to contain the alternative C-terminus, stop codon and untranslated nucleotide sequence of Lyp2 (Fig 4C). This clearly demonstrated that Lypl and Lyp2 are the alternatively spliced transcripts of a single gene.
  • Lypl and Lyp2 proteins were expressed at their predicted sizes or undergo processing in eukaryotic cells.
  • the full length cDNAs were tagged at their 5' end with a haemagglutinin (HA) epitope and transfected into COS-7 cells.
  • the cDNAs of Lypl and Lyp2 code for polypeptides of molecular weight (Mw) 92,000 and 78,000 respectively.
  • Mw molecular weight
  • Antibodies to the HA tag recognized a single protein with an apparent Mw of 96kDa in Lypl transfected cells and a single protein with an apparent molecular Mw of 80kDa in Lyp2 transfectants, indicating that these phosphatases do not undergo significant post translation modifications.
  • the full length cDNAs were cloned by PCR from oligo-dT selected mRNA, tagged with a T7 epitope and transfected into COS-7 cells.
  • the deduced amino acid sequences of Lypl and Lyp2 predict molecular weights of 92 kD and 78 kD respectively.
  • Immunoprecipitation ofthe transfected proteins with anti-T7 or anti-Lyp antibodies and blotting with the T7 antibody showed the protein Lyp2 to have an apparent molecular weight of 85 kD, slightly higher than the predicted molecular weight.
  • Lymphocytes were isolated from tonsil tissue or from peripheral blood of healthy volunteers by Ficoll-Hypaque centrifugation, following by resetting with neuraminidase treated sheep red blood cells (RBC) to isolate T lymphocytes. After isolating rosettes by FicollHypaque gradient centrifugation, T cells were released with ACT treatment (0.75% NH 4 C1 in 20 mmol/L Tris, pH 7.2) ofthe rosettes to lyse the red blood cells. The buffy layer, containing the B cells, was washed three times with PBS. The resultant T lymphocytes are typically 98% to 99% CD3+ and the B lymphocytes are typically 97% to 98.5 % CD 19+.
  • ACT treatment 0.75% NH 4 C1 in 20 mmol/L Tris, pH 7.2
  • T lymphocytes 25 x 10 6 T cells were stimulated with 2.5 ⁇ g/ml of anti-CD3 (Calbiochem) or lO ⁇ g/ml of phytohemagglutinin (PHA) (Gibco BRL) for 24 to 48 hours at 37°C in RPMI (10% FCS).
  • anti-CD3 Calbiochem
  • PHA phytohemagglutinin
  • Lyp2 expression could not detected by Northern blot analysis using a probe to the last 21 specific nucleotides. Therefore its expression, relative to Lypl, was quantified by competitive PCR on polyA+-derived single strand thymocyte cDNA. The internal standards were constructed by deleting 140bp from both Lypl and Lyp2 cDNAs.
  • Lyp appears to be a predominantly lymphoid phosphatase, although a low level of expression could also be detected in the monocyte cell line, U937.
  • Myeloid (OCI/AML3: origin and properties previously described (55)) and erythroleukemia (K562) cell lines displayed little to no expression.
  • Lyp demonstrated a high level of expression not only in the mature lymphoid tissues, but also in the thymus. In contrast to Lyp2, Lypl mRNA could not be detected in fetal liver and only a low level of expression could be seen in bone marrow.
  • the relative levels of Lypl and Lyp2 messenger RNA (mRNA) in thymocytes were quantified by competitive PCR using a synthetic cDNA as internal standard.
  • This technique involves co-amplification of a target cDNA (produced from the corresponding mRNA by reverse transcription) and ofthe internal standard.
  • the target cDNA and the internal standard use the same primer sequence, but yield PCR products of different sizes that can be resolved on gel electrophoresis.
  • the amount of target cDNA can be quantified by comparison with the amplification of various amounts of the internal standard.
  • the amount of target sequence in the sample is estimated by the amount of control producing an equivalent amounts of PCR products.
  • PCR primers The 5' primer for both Lypl and Lyp2- corresponds to nucleotides 1660-1682 with the 3' primer for LyPl- corresponding to nucleotides 2425-2447, while the 3' primer for Lyp2- corresponds to nucleotides 2075-2097.
  • cDNA was prepared from oligo (dT) selected mRNA as described previously. Aliquots of thymus cDNA were co amplified with varying amounts of internal standard for 26 cycles for Lypl and 35 cycles for Lyp2.
  • Lypl and Lyp2 were inserted into the pcDNA3 eucaryotic expression vector (Invitrogen) and a T7 tag or HA epitope (YPYDVPDYA), as a three-tandem repeat, inserted at the 5' end of the coding sequences of both Lypl and Lyp2 cDNAs. Constructs were verified by sequencing.
  • COS-7 cells were transfected with 2 ⁇ g DNA and 17 ⁇ l of Lipofectamine for 5 hours, incubated on sterile cover slips in six well plates (0.3 x 10 6 /plate) in DMEM containing 10% fetal calf serum and stained 48 hours post transfection. The COS-7 cells were then washed in PBS and fixed for 30 min at room temperature in 2% paraformaldehyde. Cell permeabilization was performed with 0.1% Triton XI 00 and after blocking non-specific sites with 5%> donkey serum, the cells were incubated with monoclonal anti-HA (1:1000) from Blco- Berkely, for 60 min at room temperature.
  • COS-7 cells transfected with either Lypl and Lyp2 displayed prominent perinuclear and cytoplasmic staining but no staining ofthe nucleus (Fig. 9). No fluorescence was noted in COS-7 cells transfected with vector alone. The pattem of staining suggests that both of these phosphatases are predominantly cytoplasmic.
  • cDNAs were inserted into the pCDNA3 eukaryotic expression vector (Invitrogen).
  • COS-7 cells (0.5 x 10 6 ) were transfected with 5 ⁇ g plasmid DNA in 50 ⁇ l of Lipofectamine (Gibco -BRL) for 5 hours according to the manufacture's instructions.
  • COS-7 cells were plated on 60mm plates in Dulbaco's modified Eagle medium (DMEM) containing 10% fetal calf serum.
  • DMEM Dulbaco's modified Eagle medium
  • Cos-7 cells were transfected with 2 ⁇ g DNA and 17 ⁇ l of Lipofectamine for 5 hours, incubated on sterile cover slips in six well plates (0.3 x 10 "6 /plate) in DMEM containing 10% fetal calf serum for 48 hours and stained. 48 hours post transfection the COS-7 cells were harvested and solubilized in cold lysis buffer (20mM Tris pH 7.5, 150 mM NaCl, ImM EDTA, 1% NP 40 and ImM PMSF).
  • NP-40 cell lysates were pre-cleared by centrifugation.
  • Immunoprecipitation of T7 tagged Lyp was carried out by the addition of l ⁇ g of T7 antibody, or by the addition of 5 ⁇ l of the Lyp anti-serum followed by the addition of 20 ⁇ l of a 50:50 suspension of protein G sepharose (Pharmacia) and incubation overnight at -4°C. Immunoprecipitates were washed three times with lysis buffer and separated by 6% SDS-PAGE. The separated proteins were electrophoretically trasferred to Hybond C Super nitro-cellulose membrane (Amersham Life Science).
  • Membranes were blocked with 5% non-fat milk and blotted with anti-T7 (1 :10,000) or with anti Lyp (1:800). Detection was performed with horseradish peroxidase conjugated second antibodies from Amersham Life Science and chemiluminescence reagent from Kirkeggard & Perry Laboratories.
  • COS-7 cells For COS-7 cells, the cells (0.5x 10 "6 /plate) were washed three times with cold PBS and solubilized in cold lysis buffer (2OmM Tris pH 7.5, 15OmM NaCl, ImM EDTA, 1% NP-40, ImM PMSF). The lysates were cleared by centrifugation. SDS sample buffer was added to the clarified lysates and resolved by 7%> SDS-PAGE . The proteins were electrophoretically transferred to Hybond-C super nitrocellulose membrane (Amersham Life Science). Membranes were blocked with 5% non fat milk and probed with HA monoclonal antibody from Blco-Berkely. Detection was performed with horseradish peroxidase conjugated sheep anti mouse purchased from (Amersham Life Science) and chemiluminescence reagent from Kirkeggard &Perry laboratories.
  • cold lysis buffer 2OmM Tris pH 7.5, 15OmM NaCl, ImM EDTA
  • Cos-7 cells were washed in PBS and fixed for 30 min at room temperature in 2% paraformaldehyde. Cell permeabilization was performed with 0.1% Triton XI 00. After blocking non-specific sites with 5%> Donkey serum, the cells were incubated for 60 min at room temperature with monoclonal anti HA tag (1:1000 in PBS) from Blco-Berkely. The cells were washed and exposed for 45 min. to cy3 conjugated affinipure Donkey anti mouse IgG (1:1000 in PBS) from Jackson Immunoresearch Laboratories, Inc. After 3-4 washes immunoreactivity was detected by fluorescence microscopy.
  • the G2 pre-preB cell line was derived from a patient with acute lymphocytic leukemia (56). All ofthe other cell lines used for the present invention were obtained from the American Type Culture Collection. All cells were maintained in RPMI 1640 containing 10% fetal calf serum.
  • Antibodies Rabbit polyclonal antibodies were raised to a mixture of two peptides of Lyp, with the amino acid sequences RTKSTPFELIQQR and SKMSLDLPEKQDG. These peptides were chosen from a potentially exposed area, as predicted by Hopp and Woods, in the non-catalytic domain. A second polyclonal antibody was raised to a bacterial fusion protein ofthe catalytic domain of Lyp (Pet vector - Novagen). After careful testing these antibodies were used for immunoprecipitation and western blotting. T7 antibody was purchased from Novagen (WI), anti-cbl, anti-Jak3 and anti-pl 10 from Santa Cruz Biotech (CA) and anti-phosphotyrosine from U.B.I. (NY).
  • Lyp proteins were first used to characterize the expression of Lyp proteins in human hematopoietic cell lines (Fig. 10).
  • a single band of 105 kD is seeen in both T cell (Jurkat) and B cell lines (Daudi and Ramos), the same size as observed upon transfection of Lypl cDNA into COS-7 cells (Fig. 6).
  • Lypl expression could not be detected in either the monocytic (U937) or myeloid (K562) cell lines, while low levels of expression could be seen in pre-B cells (G2, Al).
  • This pattem of protein expression correlates with that of Lypl mRNA observed by Northem blotting.
  • a protein ofthe predicted size of Lyp2 (85 kD) in the cell lines examined was not detected.
  • Lyp protein in primary lymphoid cells (Fig. 11) was also examined. Both thymocytes and tonsil T lymphocytes expressed Lypl, while resting T cells from peripheral blood, in addition to expressing low levels of Lypl, also expressed an 85 kD protein, recognized by both polyclonal Lyp antibodies. This is the predicted molecular weight of Lyp2, the shorter alternatively spliced form of Lypl.
  • Lyp proteins may be regulated by activation in T cells
  • normal peripheral blood T lymphocytes were incubated with either PHA, or anti-CD3 and harvested after 24 or 48 hours (Fig. 1 IB).
  • An increase in the level of Lypl protein expression was observed after 24 hours of either stimulus, with a further increase seen after 48 hours with anti-CD3.
  • the 85 kD protein could no longer be detected after a 24 hours incubation with either PHA or anti-CD3.
  • a 1.8 kb Lyp cDNA fragment was used as a probe to examine the chromosomal location of Lyp using fluorescent in situ hybridization.
  • the regional assessment of this cDNA probe was determined by the analysis of 40 well-spread metaphases.
  • Biotynylated Lyp probe was prepared by nick translation for fluorescence in situ hybridization (FISH) to normal human lymphocyte chromosomes (counterstained with propidium iodide and 4',6-diamidin-3-phenylindol-dihydrochloride, DAPI, according to published methods (43, 44).
  • the probe was detected with avidinfluorescein isothiocyanate (FITC) followed by biotinylated anti-avidin antibody antibody and avidin-FITC.
  • FITC avidinfluorescein isothiocyanate
  • Images of metaphase preparations were captured by thermoelectrically cooled charge coupled camera (Photometries, Arlington, AZ). Separate images of DAPI banded chromosomes (45) and FITC targeted chromosomes were obtained and merged electronically using image analysis software (Yale University, New Haven, CT) and pseudo coloured blue (DAPI) and yellow (FITC) as described by Boyle et al, (44). The band assignment was determined by measuring the fractional chromosome length and by analyzing the banding pattem generated by the DAPI counterstained image (46).
  • COS cells were transfected with T7-LyP cDNA, the protein immunoprecipitated with anti-T7 and used to dephosphorylate a labelled synthetic peptide, Raytide, in an in vitro phosphatase assay.
  • Raytide peptide was 33P labelled on tyrosine residues in vitro using the tyrosine kinase p60src and purified on phosphocellulose paper. Release of 33 P over time was measured in the phosphatase assay and compared to controls from untransfected cells.
  • the synthetic peptide Raytide was phosphorylated according to the method described by Guan et al., (1994)(54), on tyrosine by p ⁇ Osrc (Oncogene Science) as follows: 10 ⁇ g Raytide in 50mM Hepes pH 7.5, 10 mM MgCl 2 , 0.067% ⁇ - mercaptoethanol, 0.05 mM ATP was incubated with 300 ⁇ Cif 3 ? ATP per ml and 2 ⁇ g p ⁇ Osrc in a final volume of 30 ⁇ l. The reaction was allowed to proceed for 30 minutes at 30°C and was stopped by the addition of 120 ⁇ l 10% phosphoric acid.
  • the sample was spotted onto two 1 x 1cm sheets of P81 phophocellulose paper and extensively washed with 0.5% phosphoric acid. Phosphorylated peptide was eluted twice with 1 ml 500mM (NH 4 ) 2 CO 3 , lyophilized and resuspended in lOO ⁇ l H 2 O.
  • the phosphorylated substrate was used in the phosphatase assay as described by Stueli et al (1989)(54).
  • the phosphatase assay mixture 50 ⁇ l, contains 5 ⁇ l of xlO phosphatase (250mM Hepes pH 7.3, 50mM EDTA, lOOmM dithiothreitol), 5 ⁇ l of radioactive substrate (Raytide) and 5 ⁇ l sample (LyP immunoprecipitate) and H 2 O to final volume.
  • the assay was allowed to proceed at 30°C for the indicated time and the reaction terminated by the addition of 750 ⁇ l of a charcoal mixture (0.9M HCl, 90mM sodium pyrophosphate, 2mM NaH 2 PO 4 , 4% v/v Norit A). After centrifugation the free 33 P in the supernatant was measured.
  • a charcoal mixture 0.M HCl, 90mM sodium pyrophosphate, 2mM NaH 2 PO 4 , 4% v/v Norit A.
  • the 116 kD phosphorylated protein was identified by western blotting of Lyp immunoprecipitates from CD3 stimulated thymocytes with antibodies to various candidate proteins.
  • the 116 kD protein associated with Lypl was found to be c-Cbl (Fig. 13B), but not pl25Fak, pi 16 Jak3 or pi 10 PI3-kinase. No alteration in the amount of Cbl co-immunoprecipitating with Lyp could be detected upon anti-CD3 stimulation, suggesting that Lypl and Cbl are constitutively associated, although Cbl can be inducibly phosphorylated.
  • Lypl was found not only to co-precipitate with Cbl in COS cells, but also to reduce significantly the basal level of Cbl tyrosine phosphorylation (Fig. 13D). This suggests that Lypl may serve to regulate Cbl function and possibly that of Cbl associated proteins in lymphoid cells.
  • Example 9 cDNA for the phosphatase Lypl and the indicated kinase, in the eucaryotic expression vector pcDNA3, were transiently transfected into either the COS-7 monkey epithelial cell line (A) or the 293T human epithelial cell line as indicated. 48 hours after transfection, cells were harvested, lysates made in 1& NP-40 lysis buffer and immunoprecipitations performed with antibodies to the transfected kinase. Immunoprecipitates were washed, boiled in SDS sample buffer and electrophoresed on SDS-PAGE. After electro-transfer to nitrocellulose membrane, Western blotting was performed with anti-phosphotyrosine antibodies and chemiluminescent detection reagents.
  • Lypl co-transfection clearly resulted in a reduction in Zap-70 phosphorylation while Fyn was unaffected. Lypl could also down- regulate Zap-70 after its activation by Fyn in 293-T cells (B, lanes 3 and 4).
  • the closely related Zap family kinase Syk was also unaffected by Lypl (C). The results are shown in Figure 14.
  • Example 10 cDNA for the phosphatase Lypl and the indicated kinase, in the eucaryotic expression vector pcDNA3, were transiently transfected into the COS-7 monkey epithelial cell line. 48 hours after transfection, cells were harvested, lysates made in 1% NP-40 lysis buffer and immunoprecipitations performed with antibodies to the transfected kinase. Immunoprecipitates were washed, boiled in SDS sample buffer and electrophoesed on SDS-PAGE. After electro-transfer to nitrocellulose membrane, Western blotting was performed with anti-phosphotyrosine antibodies and chemiluminescent detection reagents.
  • Lypl clearly reduced the tyrosine phosphorylation of Jak3 (C), while having little effect upon Syk (D), possibly increasing its phosphorylation slightly; an effect not seen when Syk is co-transfected with a catalytically inactive form of Lypl (Lyp-N, where Cysteine 227 is replaced by Serine).
  • Fischer EH, Charbonneau H, Tonks HK Protein tyrosine phosphatases: A diverse family of intracellular and transmembrane enzymes. Science 253: 401, 1991.
  • Raab M, Rudd CE Hematopoietic cell phosphatase (HCP) regulates p56 lck phosphorylation and ZAP-70 binding to T cell receptor chain.
  • HCP Hematopoietic cell phosphatase
  • HePTPase inducible lymphoid-specific, protein tyrosine phosphatase
  • Tonks NK, Diltz CD, Fischer EH Purification ofthe major protein tyrosine phosphatases of human placenta. J Biol Chem 263: 6722, 1988.
  • Kozak M Point mutation define a sequence flanking the AUG initiator codon that modulates translation by eukaryotic ribosomes. Cell 44: 283, 1986.
  • Pawson T Protein modules and sinalling networks. Nature 323:573, 1995.
  • Cloutier JF, Veillette A Association of inhibitory tyrosine protein kinase p50 cs ⁇ with protein tyrosine phosphatase PEP in T cells and other hematopoietic cells. EMBO J 15:4909,1996.
  • Guan K, Broyles SS, and Dixon JE A Tyr/Ser protein phosphatase encoded by vacinia virus. Nature. 350: 359, 1991.
  • LIF Leukemia Inhibitory Factor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

L'invention porte sur un gène humain codant deux nouvelles phosphatases cytoplasmiques, Lyp1 et Lyp2, ainsi que sur des protéines et des procédés de préparation et d'utilisation du gène et des protéines précités.
PCT/CA1999/000038 1998-01-16 1999-01-18 Tyrosine phosphatases proteiniques lymphoides humaines WO1999036548A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU20432/99A AU2043299A (en) 1998-01-16 1999-01-18 Human lymphoid protein tyrosine phosphatases
CA002318697A CA2318697A1 (fr) 1998-01-16 1999-01-18 Tyrosine phosphatases proteiniques lymphoides humaines

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CA2,220,853 1998-01-16
CA 2220853 CA2220853A1 (fr) 1998-01-16 1998-01-16 Tyrosine phosphatase pour tissus lymphoides humains

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US09600358 A-371-Of-International 2000-09-25
US10/309,423 Continuation US20040006777A1 (en) 1998-01-16 2002-12-03 Human lymphoid protein tyrosine phosphatases

Publications (1)

Publication Number Publication Date
WO1999036548A1 true WO1999036548A1 (fr) 1999-07-22

Family

ID=4161759

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA1999/000038 WO1999036548A1 (fr) 1998-01-16 1999-01-18 Tyrosine phosphatases proteiniques lymphoides humaines

Country Status (3)

Country Link
AU (1) AU2043299A (fr)
CA (1) CA2220853A1 (fr)
WO (1) WO1999036548A1 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002042489A1 (fr) * 2000-11-27 2002-05-30 The Hospital For Sick Children Methodes faisant intervenir la proteine tyrosine phosphatase de lymphocyte t
EP1771581A2 (fr) * 2004-07-09 2007-04-11 The Burnham Institute Variant fonctionnel de la tyrosine phosphatase lymphoide associe aux troubles auto-immuns
WO2010075249A2 (fr) 2008-12-22 2010-07-01 Genentech, Inc. Méthode de traitement de la polyarthrite rhumatoïde avec des antagonistes de cellules b
US7833706B2 (en) 2003-01-30 2010-11-16 Celera Corporation Genetic polymorphisms associated with rheumatoid arthritis, methods of detection and uses thereof
EP1782800A3 (fr) * 2000-01-24 2010-11-24 Genzyme Corporation Inhibiteurs de la voie JAK/STAT et leurs utilisations
WO2020198293A1 (fr) * 2019-03-25 2020-10-01 Northshore University Health System Méthodes et compositions comprenant une thérapie génique immunitaire ciblée améliorée pour le traitement du cancer

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997035019A1 (fr) * 1996-03-22 1997-09-25 Genentech, Inc. Proteine tyrosine phosphatases de cellules hematopoietiques
WO1998049317A2 (fr) * 1997-04-28 1998-11-05 Sugen, Inc. Diagnostic et traitement de troubles lies a la phosphatase ou a la kinase

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997035019A1 (fr) * 1996-03-22 1997-09-25 Genentech, Inc. Proteine tyrosine phosphatases de cellules hematopoietiques
WO1998049317A2 (fr) * 1997-04-28 1998-11-05 Sugen, Inc. Diagnostic et traitement de troubles lies a la phosphatase ou a la kinase

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
COHEN S ET AL.: "Cloning and characterization of a lymphoid-specific, inducible human protein tyrosine phosphatase, Lyp", BLOOD, vol. 93, no. 6, 15 March 1999 (1999-03-15), pages 2013 - 2024, XP002103030 *
MATTHEWS R. J. ET AL.: "Characterization of hematopoietic intracellular protein tyrosine phosphatases: Description of a phosphatase containing an SH2 domain and another enriched in proline-, glutamic acid-, serine-, and threonine-rich sequences.", MOLECULAR AND CELLULAR BIOLOGY, vol. 12, no. 5, 1992, pages 2396 - 2405, XP002076841 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1782800A3 (fr) * 2000-01-24 2010-11-24 Genzyme Corporation Inhibiteurs de la voie JAK/STAT et leurs utilisations
WO2002042489A1 (fr) * 2000-11-27 2002-05-30 The Hospital For Sick Children Methodes faisant intervenir la proteine tyrosine phosphatase de lymphocyte t
US7833706B2 (en) 2003-01-30 2010-11-16 Celera Corporation Genetic polymorphisms associated with rheumatoid arthritis, methods of detection and uses thereof
EP1771581A2 (fr) * 2004-07-09 2007-04-11 The Burnham Institute Variant fonctionnel de la tyrosine phosphatase lymphoide associe aux troubles auto-immuns
EP1771581A4 (fr) * 2004-07-09 2008-07-02 Burnham Inst Variant fonctionnel de la tyrosine phosphatase lymphoide associe aux troubles auto-immuns
WO2010075249A2 (fr) 2008-12-22 2010-07-01 Genentech, Inc. Méthode de traitement de la polyarthrite rhumatoïde avec des antagonistes de cellules b
WO2020198293A1 (fr) * 2019-03-25 2020-10-01 Northshore University Health System Méthodes et compositions comprenant une thérapie génique immunitaire ciblée améliorée pour le traitement du cancer

Also Published As

Publication number Publication date
CA2220853A1 (fr) 1999-07-16
AU2043299A (en) 1999-08-02

Similar Documents

Publication Publication Date Title
Cohen et al. Cloning and characterization of a lymphoid-specific, inducible human protein tyrosine phosphatase, Lyp
US20020122801A1 (en) Integrin-linked kinase and its uses
EP0702730A1 (fr) Mutations de lignees germinales dans le gene mts et procede permettant de detecter une predisposition au cancer dans le gene mts
Shresta et al. Residual cytotoxicity and granzyme K expression in granzyme A-deficient cytotoxic lymphocytes
JPH10513359A (ja) サイクリン依存性キナーゼＣＤＫ４およびＣＤＫ６のインヒビター、ＩｎＫ４ｃ−ｐ１８およびＩｎＫ４ｄ−ｐ１９、ならびにそれらの使用
US7396920B2 (en) Tumour suppressor and uses thereof
AU2001263952A1 (en) Tumour suppressor and uses thereof
US6500653B1 (en) Nucleic acids and polypeptides which resemble RHO and which interact with cell signaling pathways and proteins
WO1999036548A1 (fr) Tyrosine phosphatases proteiniques lymphoides humaines
EP0894131A1 (fr) Recepteur d'hyaluronane humain
US20040006777A1 (en) Human lymphoid protein tyrosine phosphatases
WO1999055728A2 (fr) Genes ese et proteines
US6558950B1 (en) Methods and reagents for modulating apoptosis
WO1999002724A2 (fr) Procede d'identification de genes exprimes dans des lignees selectionnees et nouveaux genes identifies au moyen de ces procedes
CA2318697A1 (fr) Tyrosine phosphatases proteiniques lymphoides humaines
US7507801B2 (en) Adapter gene
US6534311B2 (en) Drosophila melanogaster p70S6 kinase
US7494645B2 (en) Lipid phosphate phosphatases and uses thereof for treating neuronal diseases
US6660906B1 (en) Tpl2 transgenic knockout mice
US6833255B1 (en) Drosophila melanogaster p70 S6 kinase
WO2002020786A2 (fr) Nouveaux composes et procedes
AU5775300A (en) Tankyrase2 materials and methods
US7118886B1 (en) Ese genes and proteins
CA2203706A1 (fr) Kinase jak2 humaine
WO2001051509A2 (fr) Proteine 140 associee a shc (sap-140)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2318697

Country of ref document: CA

Kind code of ref document: A

Ref document number: 2318697

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: KR

WWE Wipo information: entry into national phase

Ref document number: 09600358

Country of ref document: US

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载